drugset / Trial / NCT00161629

Study Evaluating rhBMP-2/CPM in Closed Distal Radius Fractures

NCT00161629 ↗

Phase 1 Completed 40 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedSingle-groupDouble-blindTreatment

Summary

To evaluate the safety of rhBMP-2/CPM administered to subjects presenting with closed distal radius fractures. The key safety variables comprising this assessment are: 1) incidence of delayed union; 2) median time to fracture union (assessed by the investigators); 3) incidence of local neurovascular events (those involving the region under study \[RUS\]); and 4) rate of fracture displacement. The primary objective will be met if these outcomes in the active and placebo treatment groups are at least comparable to those of the SOC control group.

Timeline

Start
2005-09
Primary completion
—
Completion
2007-01

Drugs

EvaluationDrugModalityDoseRoute
Subject rhBMP-2 Protein / enzyme biologic — —

Indications

No indication recorded.